Onco Wiki / Rote Flagge

ET-Transformation zu post-ET Myelofibrosis (~5-10% über 15 Jahre) oder zu AML / MDS (selten ~...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

Ursprung der Roten Flagge

Logik auslösen

{
  "any_of": [
    {
      "finding": "post_et_mf_transformation",
      "value": true
    },
    {
      "finding": "post_et_aml_transformation",
      "value": true
    },
    {
      "comparator": ">=",
      "finding": "blasts_pb_pct",
      "threshold": 5
    },
    {
      "comparator": ">=",
      "finding": "blasts_bm_pct",
      "threshold": 5
    },
    {
      "finding": "rapid_splenomegaly_progression",
      "value": true
    },
    {
      "finding": "leukoerythroblastic_smear",
      "value": true
    }
  ],
  "type": "composite"
}

Anmerkungen

Triggers re-route from ET 1L algorithm to PMF algorithm (post-ET MF) or AML algorithm (post-ET AML / MDS). Annual incidence is low; risk rises with disease duration + JAK2-mutation status + exposure to cytoreduction (especially anagrelide vs HU per PT-1). STUB — requires clinical co-lead signoff.

Verwendet von

Algorithmen

• ALGO-ET-1L - ALGO-ET-1L

Anwendungsgebiet

• IND-ET-2L-ANAGRELIDE - IND-ET-2L-ANAGRELIDE